Literature DB >> 22710337

Radiotherapy: radioiodine in thyroid cancer-how to minimize side effects.

Christoph Reiners, Markus Luster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22710337     DOI： 10.1038/nrclinonc.2012.101

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal.

Authors:  Pamela R Schroeder; Bryan R Haugen; Furio Pacini; Christoph Reiners; Martin Schlumberger; Steven I Sherman; David S Cooper; Kathryn G Schuff; Lewis E Braverman; Monica C Skarulis; Terry F Davies; Ernest L Mazzaferri; Gilbert H Daniels; Douglas S Ross; Markus Luster; Mary H Samuels; Bruce D Weintraub; E Chester Ridgway; Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2006-01-04       Impact factor: 5.958

2.  Radioiodine for thyroid cancer--is less more?

Authors:  Erik K Alexander; P Reed Larsen
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

Review 3.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

4.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

Authors:  Martin Schlumberger; Bogdan Catargi; Isabelle Borget; Désirée Deandreis; Slimane Zerdoud; Boumédiène Bridji; Stéphane Bardet; Laurence Leenhardt; Delphine Bastie; Claire Schvartz; Pierre Vera; Olivier Morel; Danielle Benisvy; Claire Bournaud; Françoise Bonichon; Catherine Dejax; Marie-Elisabeth Toubert; Sophie Leboulleux; Marcel Ricard; Ellen Benhamou
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

5.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Authors:  Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

6.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

Authors:  Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

7.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.

Authors:  F Pacini; P W Ladenson; M Schlumberger; A Driedger; M Luster; R T Kloos; S Sherman; B Haugen; C Corone; E Molinaro; R Elisei; C Ceccarelli; A Pinchera; R L Wahl; S Leboulleux; M Ricard; J Yoo; N L Busaidy; E Delpassand; H Hanscheid; R Felbinger; M Lassmann; C Reiners
Journal:  J Clin Endocrinol Metab       Date:  2005-12-29       Impact factor: 5.958

Review 8.  Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.

Authors:  Anna M Sawka; Lehana Thabane; Luciana Parlea; Irada Ibrahim-Zada; Richard W Tsang; James D Brierley; Sharon Straus; Shereen Ezzat; David P Goldstein
Journal:  Thyroid       Date:  2009-05       Impact factor: 6.568

9.  No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

Authors:  Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-29       Impact factor: 9.236
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.